KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Equity Average (2016 - 2025)

Sarepta Therapeutics has reported Equity Average over the past 15 years, most recently at $1.2 billion for Q4 2025.

  • Quarterly results put Equity Average at $1.2 billion for Q4 2025, down 10.48% from a year ago — trailing twelve months through Dec 2025 was $1.2 billion (down 10.48% YoY), and the annual figure for FY2025 was $1.3 billion, up 11.78%.
  • Equity Average for Q4 2025 was $1.2 billion at Sarepta Therapeutics, down from $1.3 billion in the prior quarter.
  • Over the last five years, Equity Average for SRPT hit a ceiling of $1.4 billion in Q4 2024 and a floor of $407.9 million in Q4 2022.
  • Median Equity Average over the past 5 years was $801.8 million (2022), compared with a mean of $872.7 million.
  • Biggest five-year swings in Equity Average: plummeted 53.35% in 2021 and later soared 99.03% in 2023.
  • Sarepta Therapeutics' Equity Average stood at $698.8 million in 2021, then crashed by 41.63% to $407.9 million in 2022, then surged by 99.03% to $811.8 million in 2023, then surged by 69.29% to $1.4 billion in 2024, then decreased by 10.48% to $1.2 billion in 2025.
  • The last three reported values for Equity Average were $1.2 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.3 billion (Q2 2025) per Business Quant data.